| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | RNA polymerase II transcription regulatory region sequence-specific DNA binding | ZNF500 ZSCAN29 ZNF16 ZNF135 ZKSCAN2 ZSCAN20 RFX7 ZNF763 ZNF774 ZNF691 ZNF436 ZNF572 | 1.37e-07 | 1459 | 27 | 12 | GO:0000977 |
| GeneOntologyMolecularFunction | RNA polymerase II cis-regulatory region sequence-specific DNA binding | ZNF500 ZSCAN29 ZNF16 ZNF135 ZKSCAN2 ZSCAN20 RFX7 ZNF763 ZNF774 ZNF691 ZNF572 | 2.71e-07 | 1244 | 27 | 11 | GO:0000978 |
| GeneOntologyMolecularFunction | cis-regulatory region sequence-specific DNA binding | ZNF500 ZSCAN29 ZNF16 ZNF135 ZKSCAN2 ZSCAN20 RFX7 ZNF763 ZNF774 ZNF691 ZNF572 | 3.36e-07 | 1271 | 27 | 11 | GO:0000987 |
| GeneOntologyMolecularFunction | DNA-binding transcription factor activity, RNA polymerase II-specific | ZNF500 ZSCAN29 ZNF16 ZNF135 ZKSCAN2 ZSCAN20 RFX7 MYRF ZNF774 ZNF436 ZNF572 | 9.62e-07 | 1412 | 27 | 11 | GO:0000981 |
| GeneOntologyCellularComponent | keratohyalin granule | 1.60e-05 | 5 | 27 | 2 | GO:0036457 | |
| Domain | - | ZNF500 ZSCAN29 ZNF16 ZNF135 ZKSCAN2 ZSCAN20 ZNF763 ZNF774 ZNF691 ZNF436 ZNF572 | 3.79e-10 | 679 | 25 | 11 | 3.30.160.60 |
| Domain | zf-C2H2 | ZNF500 ZSCAN29 ZNF16 ZNF135 ZKSCAN2 ZSCAN20 ZNF763 ZNF774 ZNF691 ZNF436 ZNF572 | 4.70e-10 | 693 | 25 | 11 | PF00096 |
| Domain | Znf_C2H2/integrase_DNA-bd | ZNF500 ZSCAN29 ZNF16 ZNF135 ZKSCAN2 ZSCAN20 ZNF763 ZNF774 ZNF691 ZNF436 ZNF572 | 4.78e-10 | 694 | 25 | 11 | IPR013087 |
| Domain | ZINC_FINGER_C2H2_2 | ZNF500 ZSCAN29 ZNF16 ZNF135 ZKSCAN2 ZSCAN20 ZNF763 ZNF774 ZNF691 ZNF436 ZNF572 | 1.53e-09 | 775 | 25 | 11 | PS50157 |
| Domain | ZINC_FINGER_C2H2_1 | ZNF500 ZSCAN29 ZNF16 ZNF135 ZKSCAN2 ZSCAN20 ZNF763 ZNF774 ZNF691 ZNF436 ZNF572 | 1.57e-09 | 777 | 25 | 11 | PS00028 |
| Domain | Znf_C2H2-like | ZNF500 ZSCAN29 ZNF16 ZNF135 ZKSCAN2 ZSCAN20 ZNF763 ZNF774 ZNF691 ZNF436 ZNF572 | 2.03e-09 | 796 | 25 | 11 | IPR015880 |
| Domain | Znf_C2H2 | ZNF500 ZSCAN29 ZNF16 ZNF135 ZKSCAN2 ZSCAN20 ZNF763 ZNF774 ZNF691 ZNF436 ZNF572 | 2.28e-09 | 805 | 25 | 11 | IPR007087 |
| Domain | ZnF_C2H2 | ZNF500 ZSCAN29 ZNF16 ZNF135 ZKSCAN2 ZSCAN20 ZNF763 ZNF774 ZNF691 ZNF436 ZNF572 | 2.37e-09 | 808 | 25 | 11 | SM00355 |
| Domain | SCAN | 8.75e-07 | 56 | 25 | 4 | SM00431 | |
| Domain | SCAN_BOX | 1.01e-06 | 58 | 25 | 4 | PS50804 | |
| Domain | SCAN | 1.01e-06 | 58 | 25 | 4 | PF02023 | |
| Domain | SCAN_dom | 1.01e-06 | 58 | 25 | 4 | IPR003309 | |
| Domain | Retrov_capsid_C | 1.08e-06 | 59 | 25 | 4 | IPR008916 | |
| Domain | Filaggrin | 1.72e-06 | 2 | 25 | 2 | IPR003303 | |
| Domain | KRAB | 6.19e-06 | 358 | 25 | 6 | PS50805 | |
| Domain | KRAB | 7.36e-06 | 369 | 25 | 6 | SM00349 | |
| Domain | KRAB | 7.47e-06 | 370 | 25 | 6 | IPR001909 | |
| Domain | zf-C2H2_6 | 5.24e-05 | 314 | 25 | 5 | PF13912 | |
| Domain | KRAB | 9.75e-05 | 358 | 25 | 5 | PF01352 | |
| Domain | C2H2_Znf_fam | 4.66e-04 | 24 | 25 | 2 | IPR027775 | |
| Domain | S100_CABP | 5.92e-04 | 27 | 25 | 2 | PS00303 | |
| Domain | S_100 | 5.92e-04 | 27 | 25 | 2 | PF01023 | |
| Domain | S_100 | 6.36e-04 | 28 | 25 | 2 | SM01394 | |
| Domain | S100_Ca-bd_sub | 6.36e-04 | 28 | 25 | 2 | IPR013787 | |
| Domain | S100/CaBP-9k_CS | 6.36e-04 | 28 | 25 | 2 | IPR001751 | |
| Domain | SANT | 2.03e-03 | 50 | 25 | 2 | SM00717 | |
| Domain | SANT/Myb | 2.19e-03 | 52 | 25 | 2 | IPR001005 | |
| Domain | SH3_1 | 2.01e-02 | 164 | 25 | 2 | PF00018 | |
| Domain | EF_Hand_1_Ca_BS | 2.27e-02 | 175 | 25 | 2 | IPR018247 | |
| Pubmed | 5.80e-07 | 2 | 27 | 2 | 24813994 | ||
| Pubmed | Characterization and mapping of human genes encoding zinc finger proteins. | 6.36e-07 | 22 | 27 | 3 | 1946370 | |
| Pubmed | 6.36e-07 | 22 | 27 | 3 | 1505991 | ||
| Pubmed | Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. | 1.74e-06 | 3 | 27 | 2 | 23403047 | |
| Pubmed | 1.74e-06 | 3 | 27 | 2 | 32437351 | ||
| Pubmed | GATA3 regulates FLG and FLG2 expression in human primary keratinocytes. | 1.74e-06 | 3 | 27 | 2 | 28928464 | |
| Pubmed | 8.69e-06 | 6 | 27 | 2 | 27304082 | ||
| Pubmed | Variation in genes of the epidermal differentiation complex in German atopic dermatitis patients. | 1.21e-04 | 21 | 27 | 2 | 19601998 | |
| Pubmed | Multiple genes encoding zinc finger domains are expressed in human T cells. | 2.66e-04 | 31 | 27 | 2 | 2288909 | |
| Pubmed | 5.88e-04 | 46 | 27 | 2 | 20301533 | ||
| Pubmed | A census of human transcription factors: function, expression and evolution. | 6.01e-04 | 908 | 27 | 5 | 19274049 | |
| Interaction | ZSCAN32 interactions | 2.61e-05 | 45 | 26 | 3 | int:ZSCAN32 | |
| Interaction | ZNF397 interactions | 6.85e-05 | 62 | 26 | 3 | int:ZNF397 | |
| GeneFamily | Zinc fingers C2H2-type|ZF class homeoboxes and pseudogenes | ZNF500 ZSCAN29 ZNF16 ZNF135 ZKSCAN2 ZSCAN20 ZNF763 ZNF774 ZNF691 ZNF436 ZNF572 | 4.35e-11 | 718 | 20 | 11 | 28 |
| GeneFamily | EF-hand domain containing|S100 fused type protein family | 2.43e-05 | 7 | 20 | 2 | 1350 | |
| GeneFamily | GATA zinc finger domain containing|Myb/SANT domain containing | 1.55e-03 | 53 | 20 | 2 | 532 | |
| GeneFamily | EF-hand domain containing | 2.40e-02 | 219 | 20 | 2 | 863 | |
| ToppCell | Adult-Mesenchymal-airway_smooth_muscle_cell-D175|Adult / Lineage, Cell type, age group and donor | 4.23e-06 | 182 | 27 | 4 | ad4d74d8b19976e1ccc3c5ba8013199338cf6fd8 | |
| ToppCell | Parenchymal-10x5prime-Stromal-Mesofibroblastic|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 5.78e-06 | 197 | 27 | 4 | 88a86286b9c3ea3b076d7464faec42d0392ee7f8 | |
| ToppCell | Parenchymal-10x5prime-Stromal-Mesofibroblastic-Mesothelia|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 5.78e-06 | 197 | 27 | 4 | 2773d2eb5f232a7e49da116efffcb6bf5eb90810 | |
| ToppCell | Sigmoid-Dendritic_cell-cDC1|Dendritic_cell / Region, Cell class and subclass | 6.14e-06 | 200 | 27 | 4 | 09deb831fc2c8a8867cc850f3aa094a5e48489ff | |
| ToppCell | IIH-CD8-proli_CD4|IIH / Condition, Cell_class and T cell subcluster | 9.25e-05 | 146 | 27 | 3 | 7fa6e35def3f7cffbee1e1c2f10b523bab678e14 | |
| ToppCell | COVID-19_Severe-multiplets|COVID-19_Severe / disease group, cell group and cell class | 1.04e-04 | 152 | 27 | 3 | 451745151322c2fcea22dbb3dba681e12634a510 | |
| ToppCell | COVID-19_Severe-multiplets|World / disease group, cell group and cell class | 1.28e-04 | 163 | 27 | 3 | 6db4271c2d47a9c333964f36d2c32207115e52cd | |
| ToppCell | BAL-Mild-cDC_11|Mild / Compartment, Disease Groups and Clusters | 1.30e-04 | 164 | 27 | 3 | 4bd9629d054545d1e3f9e5c127b5ac2388637106 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid-Dendritic-CD1c-positive_myeloid_dendritic_cell-DC2_(CD1c+_dendritic_cell)-DC2_L.1.2.1.3|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.33e-04 | 165 | 27 | 3 | 76abebe80e5f8bf44825bb619ae86fcb6f66ffeb | |
| ToppCell | Influenza_Severe-pDC|Influenza_Severe / Disease group and Cell class | 1.35e-04 | 166 | 27 | 3 | b43a5cd4d28118cf6e56a435deb8ea9435608a90 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-DC-DC1-B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.35e-04 | 166 | 27 | 3 | c8a7d94ed762e5e045ab5f74eef691ddc5f74993 | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.38e-04 | 167 | 27 | 3 | 7cb1b11e8e24a10115e46ffbb74889e672a7a026 | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.38e-04 | 167 | 27 | 3 | bb53a478b5d821d6d82c15bc4ed075b67682457c | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.38e-04 | 167 | 27 | 3 | e228b8373ffd4436e6b944e26d0fadf3ac289b21 | |
| ToppCell | COVID-19-kidney-PEC|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.40e-04 | 168 | 27 | 3 | a086c306be430adf0632ba53e98cd8014d2de330 | |
| ToppCell | BAL-Mild-Myeloid-cDC-cDC-cDC_11|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 1.43e-04 | 169 | 27 | 3 | e3410ccb3f85811c75694e286115803911169a2f | |
| ToppCell | BAL-Mild-Myeloid-cDC-cDC-cDC_11|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.43e-04 | 169 | 27 | 3 | a4f610d07c3ba5537f4497f523669b914f7eddc1 | |
| ToppCell | Children_(3_yrs)-Mesenchymal-myofibroblast_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.53e-04 | 173 | 27 | 3 | 1f16d47f5548e257e4b17f8070c5619780a9c5fd | |
| ToppCell | 3'-GW_trimst-2-LargeIntestine-Hematopoietic-B_cells-CLP|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.53e-04 | 173 | 27 | 3 | b367b62309389e8b6a65de83c2434dc8ec905985 | |
| ToppCell | BAL-Control-Myeloid-cDC-cDC-cDC_11|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 1.55e-04 | 174 | 27 | 3 | c8cec89369cf3896c5626e447051e76a142cb6df | |
| ToppCell | AT1_cells-HP_01|World / lung cells shred on cell class, cell subclass, sample id | 1.61e-04 | 176 | 27 | 3 | 458720776b0151cd55acc352d509599cb62f0ca8 | |
| ToppCell | Control-Epithelial_alveolar-AT_1-Differentiating_AT1|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.63e-04 | 177 | 27 | 3 | 9af14a056eb6d88c6f11b09f6d4c0d3448d647d5 | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.69e-04 | 179 | 27 | 3 | 04ce3673e46606f63d9c87bcba3a64c96817d812 | |
| ToppCell | Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.69e-04 | 179 | 27 | 3 | 4f6ca313b78aa93557937a046c44dcf8bcc9963c | |
| ToppCell | Children_(3_yrs)-Mesenchymal-myofibroblast_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.72e-04 | 180 | 27 | 3 | 01f2e5d96016823482f89ba503d007d4bd88eeac | |
| ToppCell | IPF-Epithelial-Mesothelial|IPF / Disease state, Lineage and Cell class | 1.72e-04 | 180 | 27 | 3 | 1fa54bf4dba72866b2295639d991af639341bc08 | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.74e-04 | 181 | 27 | 3 | b45b11428d13950369347e051d4d517efb2bd4fd | |
| ToppCell | LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.83e-04 | 184 | 27 | 3 | 42ce855b4f8475a8298192feec785bdc69bc5bb0 | |
| ToppCell | tumor_Lung-Fibroblasts-Mesothelial_cells|tumor_Lung / Location, Cell class and cell subclass | 1.83e-04 | 184 | 27 | 3 | b0a251030d127858e68cf164be158f209a4d720f | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.86e-04 | 185 | 27 | 3 | c82eab551f65ecebe6db908eda9f9eb3414693c7 | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.89e-04 | 186 | 27 | 3 | 4e94158db52df41d71e67b02b9895a358eebee0f | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.89e-04 | 186 | 27 | 3 | 3aebe163799109ffc67e4e10ee47c2dd0886a92c | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-myofibroblast_cell|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 1.92e-04 | 187 | 27 | 3 | c104fbfef2d0bef64077ac721edf2379fd59d547 | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.92e-04 | 187 | 27 | 3 | 58d48128547ee3513d0bf7f78e61b76b1c472ca9 | |
| ToppCell | Control-Fibroblasts-Other_FB|Control / group, cell type (main and fine annotations) | 1.92e-04 | 187 | 27 | 3 | bd3739c4a52aa1ba5deffd778e113a9800f7e158 | |
| ToppCell | Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1-D150|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 1.92e-04 | 187 | 27 | 3 | 4ae7465174e0295d2c3b614b321a3b2f514dd22a | |
| ToppCell | Mesenchymal-myofibroblast_cell|World / Lineage, Cell type, age group and donor | 1.98e-04 | 189 | 27 | 3 | 44e37f88137bb249933eb615235b2cf2ae7f3925 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.98e-04 | 189 | 27 | 3 | 2cfb4d12f75678d1619f4743838a0e954bd57761 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.98e-04 | 189 | 27 | 3 | 127ad2ba3e794df8cce2eee3e4171bccb5aad51b | |
| ToppCell | COVID-19-Myeloid-DC1|Myeloid / Condition, Lineage and Cell class | 2.04e-04 | 191 | 27 | 3 | 4be3c6287965fe3a2f109d26f68bdc2fa393f99b | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.08e-04 | 192 | 27 | 3 | bfab13793e54de2550ee171397f7ece0625cdb4a | |
| ToppCell | proximal-3-Hematologic-Platelet/Megakaryocyte|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 2.08e-04 | 192 | 27 | 3 | f5f83dec37dff32a0c471cb05d23d13b0b0ad0c9 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.08e-04 | 192 | 27 | 3 | b54b0d5b88139905521c8d5d58332e89c08d589c | |
| ToppCell | proximal-Hematologic-Platelet/Megakaryocyte|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 2.08e-04 | 192 | 27 | 3 | 522d1bb15edf1d6006b80289bd3baadb99584ae8 | |
| ToppCell | proximal-Hematologic-Platelet/Megakaryocyte-3|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 2.08e-04 | 192 | 27 | 3 | 57899a905ca3e336bb7f31edc6418a2546b9891a | |
| ToppCell | COVID-19-Fibroblasts-Other_FB|COVID-19 / group, cell type (main and fine annotations) | 2.11e-04 | 193 | 27 | 3 | e6b75be08e33c1de079fb5c02f0b4468128b369c | |
| ToppCell | IPF-Epithelial-Mesothelial|Epithelial / Disease state, Lineage and Cell class | 2.14e-04 | 194 | 27 | 3 | d8a26da856a85e3d001d406e992cb18fdd58baef | |
| ToppCell | Parenchymal-NucSeq-Stromal-Mesofibroblastic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.17e-04 | 195 | 27 | 3 | a52685f76eca269a7d2de8dfc317439483e233fa | |
| ToppCell | PBMC-Control-cDC_11|Control / Compartment, Disease Groups and Clusters | 2.17e-04 | 195 | 27 | 3 | 74d560ff0f47512441c305885c5c16272f711b8e | |
| ToppCell | Parenchymal-NucSeq-Stromal-Mesofibroblastic-Mesothelia|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.17e-04 | 195 | 27 | 3 | 224deeba2f60def6543a55bb4f5ee6c7fdab3f02 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.20e-04 | 196 | 27 | 3 | b8759e6231e0254797d6c30930407b79440c57bb | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.24e-04 | 197 | 27 | 3 | 44673c38384453207871d3fd8e8ba9093cc06bc5 | |
| ToppCell | Bronchial-10x5prime-Stromal-Mesofibroblastic-Mesothelia|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 2.24e-04 | 197 | 27 | 3 | 26888af95a7cc082a1f1218af35b1f07cb9436ed | |
| ToppCell | Bronchial-10x5prime-Stromal-Mesofibroblastic|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 2.24e-04 | 197 | 27 | 3 | 438de7f0d35d81d5f5e41dcef7b2c54b6da03df4 | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_myofibroblast|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.24e-04 | 197 | 27 | 3 | 6d0d68d460243a0259ada93ebda40fa7b3088eeb | |
| ToppCell | Influenza-Influenza_Severe-Myeloid-pDC|Influenza_Severe / Disease, condition lineage and cell class | 2.24e-04 | 197 | 27 | 3 | e8e6f71e6dc8a695e4321a18543c1df63dd62f3e | |
| ToppCell | Biopsy_Other_PF-Mesenchymal-Mesothelial_cells|Biopsy_Other_PF / Sample group, Lineage and Cell type | 2.27e-04 | 198 | 27 | 3 | 86736f01e61bf4961f060b24ee1f1f48340737dd | |
| ToppCell | Biopsy_Control_(H.)-Mesenchymal-Mesothelial_cells|Biopsy_Control_(H.) / Sample group, Lineage and Cell type | 2.31e-04 | 199 | 27 | 3 | ca970114b5aef4518ce580897a62ac88688b2671 | |
| ToppCell | Biopsy_IPF-Mesenchymal-Mesothelial_cells|Biopsy_IPF / Sample group, Lineage and Cell type | 2.34e-04 | 200 | 27 | 3 | 553386523fd8f8f36617a0d81032224b7ddce442 | |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_adventitial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.34e-04 | 200 | 27 | 3 | ad3fdcef895400f929f2ae12ff9bd85fd46adb3a | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.34e-04 | 200 | 27 | 3 | 34f52003988ce6329d8deeee1ab875fa77e01e9d | |
| ToppCell | Bronchial-NucSeq-Stromal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.34e-04 | 200 | 27 | 3 | 389cc775c8419d90fb77cd794376d2160a7bf44e | |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.34e-04 | 200 | 27 | 3 | e8462395fee0a532d1e7ec7f1795f28c42af6541 | |
| ToppCell | Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.34e-04 | 200 | 27 | 3 | 58b38f9a484ee94191091a0659ed62ebed2d4a14 | |
| Disease | cholesteryl ester 24:6 measurement | 1.03e-05 | 6 | 25 | 2 | EFO_0021449 | |
| Disease | rheumatoid arthritis, anti-citrullinated protein antibody seropositivity, rheumatoid factor seropositivity measurement | 3.94e-04 | 170 | 25 | 3 | EFO_0000685, EFO_0007791, EFO_0007837 | |
| Disease | asthma | 3.44e-03 | 751 | 25 | 4 | MONDO_0004979 | |
| Disease | acylcarnitine measurement | 5.17e-03 | 127 | 25 | 2 | EFO_0005059 | |
| Disease | respiratory system disease | 6.68e-03 | 145 | 25 | 2 | EFO_0000684 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| HHVHSRLNSQSSSEH | 336 | Q8NDL9 | |
| HHEQARDSSRHSASQ | 496 | P20930 | |
| TRHSGSRHHEASSQA | 581 | P20930 | |
| SRHHEASSQADSSRH | 586 | P20930 | |
| RHGSRHQQSADSSRH | 1356 | P20930 | |
| HHEPSTRAGSSRHSQ | 1561 | P20930 | |
| GSHHQLQSADSSRHS | 2006 | P20930 | |
| SHHKQARDSSRHSTS | 2441 | P20930 | |
| SHHQQSADSSRHSGI | 2656 | P20930 | |
| RSSAGERHGSHHQQS | 2971 | P20930 | |
| ERHGSHHQQSADSSR | 2976 | P20930 | |
| RHGSRHQQSADSSRH | 3301 | P20930 | |
| QGSHHEQARDSSRHS | 3411 | P20930 | |
| HHEASTQADSSRHSQ | 3506 | P20930 | |
| RSSSSAPHHNHRSGT | 531 | Q08289 | |
| RSSRASHFQSHSSER | 2321 | Q5D862 | |
| SHFQSHSSERQRHGS | 2326 | Q5D862 | |
| RHGTIERTSNGQHFH | 2356 | Q86XX4 | |
| SKEQGHHRSNHRNST | 986 | Q6UVM3 | |
| HHRSNHRNSTSSDQS | 991 | Q6UVM3 | |
| HPEEHGRQSHSSSSF | 811 | Q2TAC2 | |
| SRHSSSHRLNEQSRH | 621 | Q9NPG1 | |
| RSRGSENSHSSQSFH | 71 | Q6PI97 | |
| SFTTSNHSVQNRDHR | 246 | Q7Z7G1 | |
| FSNSSHLRTHQRTHS | 141 | Q7Z3I7 | |
| RSSHLAQHQRTHTGE | 261 | Q9C0F3 | |
| TFSHSSSLSQHERTH | 446 | P52742 | |
| SFSHSSSLSQHERTH | 586 | P52742 | |
| FSNSSSFGVHHRTHT | 236 | Q5VV52 | |
| NSSHFSAHRRTHAGG | 1026 | P17040 | |
| SSHSHQSQIYRSHNV | 1371 | O15027 | |
| FLRHHSRTSNSTGAE | 226 | Q96DM3 | |
| SVTHRSSQAASHRHS | 386 | Q8TEJ3 | |
| SRGAQAAACHTSHHS | 91 | Q96PX9 | |
| FSQSSHLVTHQRTHT | 356 | Q6NX45 | |
| QSQSRHHDTHFGRLT | 1011 | Q2KHR2 | |
| GHSDFSRHQSHHSSE | 276 | P17020 | |
| SSHFSAHRRVHTGEN | 871 | Q63HK3 | |
| FNNSSHFSAHRRIHT | 771 | Q8IWY8 | |
| HSSSSFQAHKRTHTG | 266 | Q0D2J5 | |
| GFSDRSNFSTHQRVH | 361 | O60304 | |
| QSLHTHQDTQGTSHR | 1091 | Q9Y2G1 |